purpose to assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (deb-tace) in liver cancer patients with diferent times of previous conventional transarterial chemoembolization(ctace) treatments.
methods 367 liver cancer patients about to receive deb-tace treatment were enrolled in this prospective cohort study. all patients were divided into no previous ctace group (npc group), 1–2 times previous ctace group (pc group) and triple or above previous ctace group (tpc group) according to the times of previous ctace treatments.
results there was no diference in complete response(cr) (p =0.671) and objective response rate (orr) (p =0.062) among three groups. additionally, no diference in overall survival (os) among groups (p =0.899) was found. as to liver function,most liver function indexes were deteriorative at 1 week after deb-tace operation, but returned to baseline at 1–3 months after deb-tace operation in all three groups, while percentage of abnormal total bile acid (tba) patients was higher in tpc group than npc and pc groups at 1–3 month post-deb-tace (p= 0.018). as for safety profles, the incidence of pain during deb-tace operation was lower in tpc group compared to npc and pc groups (p = 0.005), while no diference of other adverse events was found during and 1 month post-deb-tace treatment among three groups.
结果：三组间完全缓解率(cr) (p=0.671)和客观反应率(orr) (p=0.062)无差异。总生存率(os)无差异(p=0.899)，在肝功能方面，大部分肝功能指标在deb-tace术后1周开始恶化，但在deb-tace术后1~3个月恢复到基线水平，而tpc组胆汁酸(tba)明显高于npc和pc组(p=0.018)。在安全性方面，tpc组术后疼痛发生率低于npc组和pc组(p=0.005)，而3个组在治疗后1个月内其他不良事件发生率均无明显差异。
conclusion deb-tace treatment was equally efficient and tolerated in liver cancer patients with diferent times of previous ctace treatments.